For more information, please visit the Fund’s website

[shapanwwuom]

The Innovation and Technology Venture Fund of the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government will co-invest with venture capital funds selected as co-investment partners of the Innovation and Technology Venture Fund in eligible local innovation and technology start-ups at a matching ratio of approximately 1 (Innovation and Technology Venture Fund): 2 (co-investment partners), enriching the local innovation and technology ecosystem. An optimization plan for the Innovation and Technology Venture Capital Fund has also been launched to invest in start-ups in strategic industries.


About eGarden Ventures

eGarden Ventures is a venture capital fund focused on startups in emerging sectors. We are passionate about entrepreneurship and are committed to supporting startup founders in all aspects. In addition to british student data providing capital, we also provide strategic resources and professional guidance to help companies achieve continued growth and prosperity after the investment.

About Qingsong Capital

Qingsong Capital is an entrepreneurial private equity investment institution focusing on biotechnology and healthcare. Its management team has a deep medical industry background and private equity investment experience. We are committed to growing together with the best innovative biomedical companies and promoting technological and commercial innovation in China's life science and healthcare industries. We insist on research-driven investment, deeply participate in the development of invested companies, and delve deeply into biotechnology, innovative drugs, innovative medical devices, precision medicine and services, and the intersection of the big health industry and cutting-edge technology.

Since its establishment, the fund has completed investments in star projects in multiple sub-sectors, and many projects have been listed, including United Imaging Healthcare (688271.SH), Sinocell (688520.SH), SinoPac (301047.SZ), Juzi Biopharm (02367.HK), and Ruike Biopharm (02179.HK), etc.

About K2VC

Founded in 2010, K2VC focuses on early-stage investments and is committed to promoting technological progress, industrial upgrading, business model innovation and the evolution of people's lifestyles. Xiangfeng manages a dual-currency fund in RMB and USD. As of 2022, the management scale is approximately RMB 10 billion, and it has invested in more than 700 start-ups.